Precision medicine aims to tailor medical treatments to each patient’s individual genetic profile and biology. Cancer researchers know that patients with particular mutations may respond better to certain types of drugs. Understanding tumor genetics helps biologists and geneticists create agents that target those tumors with greater efficacy.
G-202, a prodrug currently being investigated in Phase II clinical trials, is in a class of drugs that uses a biomarker for targeting. Identification of disease-specific biomarkers is essential to help predict patient reactions and speed up the process for treatment approval. Combining the biomarker research with proven immunotherapies will hopefully lead to increases in cancer survival rates.